Background After the first investigational study on the use of extracorporeal photopheresis
for the treatment of cutaneous T‐cell lymphoma was published in 1983 with its subsequent …

Background Following the first investigational study on the use of extracorporeal
photopheresis for the treatment of cutaneous T‐cell lymphoma published in 1983, this …

Background Following the first investigational study on the use of extracorporeal
photopheresis for the treatment of cutaneous T‐cell lymphoma published in 1983, this …

This synopsis reviews recent developments in dermatological phototherapy. UVA1
phototherapy (340-400 nm) is effective in the treatment of inflammatory skin diseases such …

Extracorporeal photopheresis (ECP) has been used for over 30 years in the treatment of
erythrodermic cutaneous T‐cell lymphoma (CTCL) and over 20 years for chronic graft …

Extracorporeal photopheresis (ECP) has been used for over 35 years in the treatment of
erythrodermic cutaneous T‐cell lymphoma (CTCL) and over 20 years for chronic and acute …

Edelson et al. first reported the use of extracorporeal photopheresis (ECP) to treat cutaneous
T‐cell lymphoma (CTCL) in 1987, and since then several studies reporting response rates …

Extracorporeal photopheresis (ECP) has been in clinical use for over three decades after
receiving FDA approval for the palliative treatment of the Sézary Syndrome variant of …

Photopheresis is an apheresis–based therapy that is currently available at approximately 70
medical centers worldwide. Recent evidence indicates that extracorporeal photopheresis …

Extracorporeal photopheresis (ECP) is a leukapheresis-based therapy that uses 8-
methoxypsoralen and ultraviolet A irradiation. Used alone or in combination with biological …